These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
109 related articles for article (PubMed ID: 21204744)
21. Rotavirus vp7 antigen produced by Lactococcus lactis induces neutralizing antibodies in mice. Perez CA; Eichwald C; Burrone O; Mendoza D J Appl Microbiol; 2005; 99(5):1158-64. PubMed ID: 16238746 [TBL] [Abstract][Full Text] [Related]
22. Therapeutic drug delivery by genetically modified Lactococcus lactis. Steidler L; Rottiers P Ann N Y Acad Sci; 2006 Aug; 1072():176-86. PubMed ID: 17057198 [TBL] [Abstract][Full Text] [Related]
23. [Relief effect of beta-galactosidase genetically engineered lactococcus lactis on the cell toxicity caused by lactose]. Liu X; Lü XY; Yu Q; Zhang CW Sichuan Da Xue Xue Bao Yi Xue Ban; 2006 Jan; 37(1):52-4. PubMed ID: 16468641 [TBL] [Abstract][Full Text] [Related]
24. Modulation of gut-associated lymphoid tissue functions with genetically modified Lactococcus lactis. Rottiers P; De Smedt T; Steidler L Int Rev Immunol; 2009; 28(6):465-86. PubMed ID: 19954359 [TBL] [Abstract][Full Text] [Related]
25. Stimulation of respiratory immunity by oral administration of Lactococcus lactis. Villena J; Medina M; Vintiñi E; Alvarez S Can J Microbiol; 2008 Aug; 54(8):630-8. PubMed ID: 18772925 [TBL] [Abstract][Full Text] [Related]
26. Development of an enteric-coated formulation containing freeze-dried, viable recombinant Lactococcus lactis for the ileal mucosal delivery of human interleukin-10. Huyghebaert N; Vermeire A; Neirynck S; Steidler L; Remaut E; Remon JP Eur J Pharm Biopharm; 2005 Aug; 60(3):349-59. PubMed ID: 15927456 [TBL] [Abstract][Full Text] [Related]
27. Genome analysis of lactic acid bacteria in food fermentations and biotechnological applications. Nga BH Curr Opin Microbiol; 2005 Jun; 8(3):307-12. PubMed ID: 15939354 [TBL] [Abstract][Full Text] [Related]
28. Prevention and treatment of colitis with Lactococcus lactis secreting the immunomodulatory Yersinia LcrV protein. Foligne B; Dessein R; Marceau M; Poiret S; Chamaillard M; Pot B; Simonet M; Daniel C Gastroenterology; 2007 Sep; 133(3):862-74. PubMed ID: 17678918 [TBL] [Abstract][Full Text] [Related]
29. Mucosal vaccine delivery of antigens tightly bound to an adjuvant particle made from food-grade bacteria. van Roosmalen ML; Kanninga R; El Khattabi M; Neef J; Audouy S; Bosma T; Kuipers A; Post E; Steen A; Kok J; Buist G; Kuipers OP; Robillard G; Leenhouts K Methods; 2006 Feb; 38(2):144-9. PubMed ID: 16414272 [TBL] [Abstract][Full Text] [Related]
30. Dual inducible expression of recombinant GFP and targeted antisense RNA in Lactococcus lactis. Oddone GM; Mills DA; Block DE Plasmid; 2009 Sep; 62(2):108-18. PubMed ID: 19523486 [TBL] [Abstract][Full Text] [Related]
31. Current prophylactic and therapeutic uses of a recombinant Lactococcus lactis strain secreting biologically active interleukin-12. Bermúdez-Humarán LG; Cortes-Perez NG; Ah-Leung S; Lefèvre F; Yang G; Pang Q; Wu C; Zeng Y; Adel-Patient K; Langella P J Mol Microbiol Biotechnol; 2008; 14(1-3):80-9. PubMed ID: 17957114 [TBL] [Abstract][Full Text] [Related]
32. In situ delivery of therapeutic cytokines by genetically engineered Lactococcus lactis. Steidler L Meded Rijksuniv Gent Fak Landbouwkd Toegep Biol Wet; 2001; 66(3b):551, 553-6. PubMed ID: 15954652 [No Abstract] [Full Text] [Related]
33. Secretion of human interferon-beta 1b by recombinant Lactococcus lactis. Zhuang Z; Wu ZG; Chen M; Wang PG Biotechnol Lett; 2008 Oct; 30(10):1819-23. PubMed ID: 18575814 [TBL] [Abstract][Full Text] [Related]
34. Nisin-controlled extracellular production of apidaecin in Lactococcus lactis. Zhou XX; Wang YB; Pan YJ; Li WF Appl Microbiol Biotechnol; 2008 Apr; 78(6):947-53. PubMed ID: 18286279 [TBL] [Abstract][Full Text] [Related]
36. In situ delivery of cytokines by genetically engineered Lactococcus lactis. Steidler L Antonie Van Leeuwenhoek; 2002 Aug; 82(1-4):323-31. PubMed ID: 12369199 [TBL] [Abstract][Full Text] [Related]
37. Immunomodulation by genetically engineered lactic acid bacteria. Van Huynegem K; Loos M; Steidler L Front Biosci (Landmark Ed); 2009 Jun; 14(13):4825-35. PubMed ID: 19482589 [TBL] [Abstract][Full Text] [Related]
38. Nasal administration of Lactococcus lactis improves local and systemic immune responses against Streptococcus pneumoniae. Medina M; Villena J; Salva S; Vintiñi E; Langella P; Alvarez S Microbiol Immunol; 2008 Aug; 52(8):399-409. PubMed ID: 18667039 [TBL] [Abstract][Full Text] [Related]
39. Human scFv SIgA expressed on Lactococcus lactis as a vector for the treatment of mucosal disease. Yuvaraj S; Al-Lahham S; Marreddy RK; Dijkstra G; Wolken WA; Lolkema JS; Helfrich W; Johansen FE; Peppelenbosch MP; Bos NA Mol Nutr Food Res; 2008 Aug; 52(8):913-20. PubMed ID: 18504703 [TBL] [Abstract][Full Text] [Related]
40. [Expression of helicobacter pylori alpA gene in lactococcus lactis and its immunogenicity analysis]. Sun ZL; Bi YW; Bai CM; Gao DD; Li ZH; Dai ZX; Li JF; Xu WM Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2010 Mar; 26(3):203-6. PubMed ID: 20230679 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]